Evaluating the Cost-Effectiveness of RSV Vaccination for the Elderly in the Netherlands: A Promising Public Health Strategy

Speaker(s)

Westra T1, Zeevat F2, Lempers VJ3, Ghaswalla P4, Joshi K4, Wilschut JC2, Van Der Pol S5, Postma MJ6, Boersma C7
1Moderna, Inc., Netherlands, de Wijk, Netherlands, 2University of Groningen, University Medical Center Groningen, Groningen, GR, Netherlands, 3Moderna, Inc., Netherlands, Amsterdam, Netherlands, 4Moderna, Inc., Cambridge, MA, USA, 5Health-Ecore, Zeist, UT, Netherlands, 6University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 7University of Groningen, University Medical Center Groningen, Zeist, UT, Netherlands

Presentation Documents

OBJECTIVES: The Dutch Health Council is currently evaluating the introduction of an RSV vaccination program for older adults. The council advises the Ministry of Health based on seven criteria, one of which is the cost-effectiveness of the vaccination strategy. This study aims to assess the cost-effectiveness of a public RSV vaccination program for individuals aged ≥60 years in the Netherlands.

METHODS: A static decision-tree model was adapted to reflect the situation in the Netherlands. The burden of disease data was sourced from previous epidemiological studies, while costs and utilities were taken from existing cost-effectiveness studies. The cost-effectiveness was evaluated under various scenarios in accordance with Dutch Health Technology Assessment guidelines. An intensive sensitivity analysis was conducted to test the robustness of the results. The model assumed a two-year timeframe in the base case and trial data were used to project waning over time.

RESULTS: RSV vaccination results in a relevant reduction in RSV disease. Over a two-year timeframe, the program is projected to result in €18 million in direct medical cost savings and €90 million in indirect cost savings on production losses. A total of 7175 Quality-Adjusted Life Years (QALYs) will be gained. Considering the currently published listprices of RSV vaccines, the Incremental Cost Effectiveness Ratio (ICER) was just above €50,000 per QALY gained, the Dutch willingness-to-pay threshold for preventive interventions. The ICER is sensitive to assumptions regarding the burden of disease, vaccine price, target age groups, and the duration of vaccine-induced protection.

CONCLUSIONS: Based on currently published listprices, the estimated base case ICER is just above the willingness-to-pay threshold of €50,000 per QALY gained. Sensitivity analysis show that a public RSV vaccination program for all individuals aged ≥60 years is likely cost-effective.

Code

EE160

Topic

Economic Evaluation, Epidemiology & Public Health

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis, Public Health

Disease

Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory), Vaccines